Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval

The aim of this study was to evaluate how often the European Medicines Agency (EMA) has authorized drugs based on nonrandomized studies and whether there is an association between treatment effects and EMA preference for further testing in randomized clinical trials (RCTs).
Source: Journal of Clinical Epidemiology - Category: Epidemiology Authors: Tags: Review Source Type: research